牛牛AI助理已提取核心訊息
60 Degrees Pharmaceuticals, Inc., a pharmaceutical company specializing in infectious disease treatments, has announced the completion of a 1-for-12 reverse stock split of its common stock, effective August 12, 2024. The reverse stock split was approved by the company's stockholders on July 16, 2024, and the final ratio was determined by the Board of Directors on July 19, 2024. The split, which was filed with the Secretary of State of Delaware on July 30, 2024, is intended to comply with Nasdaq's minimum bid price requirement. The company's common stock will continue trading on the Nasdaq under the symbol 'SXTP' with a new CUSIP number. No fractional shares were issued; instead, fractional amounts were rounded up to the nearest whole share. The reverse stock split affects all stockholders uniformly and does not change their percentage equity interest in the company. Equity Stock Transfer, LLC will act as the agent for the reverse stock split, and stockholders do not need to take any action to receive post-split shares.
60 Degrees Pharmaceuticals, Inc., a pharmaceutical company specializing in infectious disease treatments, has announced the completion of a 1-for-12 reverse stock split of its common stock, effective August 12, 2024. The reverse stock split was approved by the company's stockholders on July 16, 2024, and the final ratio was determined by the Board of Directors on July 19, 2024. The split, which was filed with the Secretary of State of Delaware on July 30, 2024, is intended to comply with Nasdaq's minimum bid price requirement. The company's common stock will continue trading on the Nasdaq under the symbol 'SXTP' with a new CUSIP number. No fractional shares were issued; instead, fractional amounts were rounded up to the nearest whole share. The reverse stock split affects all stockholders uniformly and does not change their percentage equity interest in the company. Equity Stock Transfer, LLC will act as the agent for the reverse stock split, and stockholders do not need to take any action to receive post-split shares.
專注傳染病治療的藥品公司60 Degrees Pharmaceuticals, Inc.已宣佈完成普通股1比12的股票轉債，於2024年8月12日起生效。2024年7月16日，公司的股東批准了股票轉債，最終比率由董事會在2024年7月19日確定。這項股票轉債於2024年7月30日向特拉華州國務卿登記。這個轉債旨在遵守納斯達克的最低買入價格要求。公司的普通股將繼續在納斯達克上交易，標爲'SXTP'，有新的CUSIP編碼。沒有發行碎股，而是將碎股取整到最近的整股。股票轉債對所有股東的影響是相同的，不會改變他們在公司中的持股比例。Equity Stock Transfer, LLC將擔任股票轉債的代理商，股東不需要採取任何行動來接收發股後的股票。
專注傳染病治療的藥品公司60 Degrees Pharmaceuticals, Inc.已宣佈完成普通股1比12的股票轉債，於2024年8月12日起生效。2024年7月16日，公司的股東批准了股票轉債，最終比率由董事會在2024年7月19日確定。這項股票轉債於2024年7月30日向特拉華州國務卿登記。這個轉債旨在遵守納斯達克的最低買入價格要求。公司的普通股將繼續在納斯達克上交易，標爲'SXTP'，有新的CUSIP編碼。沒有發行碎股，而是將碎股取整到最近的整股。股票轉債對所有股東的影響是相同的，不會改變他們在公司中的持股比例。Equity Stock Transfer, LLC將擔任股票轉債的代理商，股東不需要採取任何行動來接收發股後的股票。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了